Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A-induced experimental model
Rescue of autoimmune hepatitis by soluble MHC class Ⅱ molecules in an altered concanavalin A-induced experimental model作者机构:Laboratory of ImmunologyDepartment of BiologyUniversity of CreteHeraklionCreteGreece
出 版 物:《Animal Models and Experimental Medicine》 (动物模型与实验医学(英文))
年 卷 期:2020年第3卷第3期
页 面:264-272页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题:autoimmune hepatitis cytokines immunosuppression inflammation
摘 要:Background:Soluble major histocompatibility complex class II(sMHCII)molecules have been described to maintain tolerance through the suppression of autoreactive T *** order to evaluate their ability to rescue autoimmune hepatitis(AIH)symptoms,the present work attempted to administer sMHCII molecules to an in vitro as well as in vivo concanavalin A(ConA)-induced AIH ***:The in vitro AIH model consisted of splenocyte stimulation with ConA in the presence or absence of serum-isolated sMHCII *** in vivo ConAmodified model with or without sMHCII treatment was *** cytokine profile in culture supernatants and serum was tested by *** markers were evaluated by immunofluorescence,while cell proliferation by tritiated thymidine *** symptoms were assessed by daily observations for the establishment of a disease severity scoring system and liver histology was evaluated using a biomolecular ***:The presence of sMHCII molecules in the ConA-stimulated cell cultures leads to a significant reduction of cell *** administration of sMHCII molecules to the ConA-treated animals showed a significant reduction in the levels of IL-2,IL-4,and IL-10,as well as a decrease in the number of spleen CD4+and CD8+*** development of a scoring system,it was shown that the sMHCII treatment was accompanied by a slower progression of the disease,while rescuing fibrotic liver ***:The results presented in this study confirm the ability of sMHCII proteins to alleviate autoimmune hepatitis,possibly highlighting new therapeutic approaches for autoimmune diseases.